FFO
ORKA

Fortitude Family Office’s Oruka Therapeutics ORKA Stock Holding History

Fortitude Family Office’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Hold
12
– – ﹤0.01% 1702
2026
Q1 		$589 Buy
+12
New +$417 ﹤0.01% 1669

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fortitude Family Office's ORKA Position: Q2 2026 in Review

Fortitude Family Office held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 12 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

Fortitude Family Office first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Fortitude Family Office held 12 shares of Oruka Therapeutics worth $1.14K as of Q2 2026.
  • Fortitude Family Office left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1702 holding.
  • Fortitude Family Office first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.